Home  /  Resource Library  /  Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

ASH 2020: Results of a phase II study investigating idasanutlin combined with venetoclax and obinutuzumab for treatment of relapsed follicular and diffuse large b-cell lymphoma.